Viktor Arnkil

Anocca AB is a Swedish biopharmaceutical company that is developing next-generation T-cell immunotherapies for the treatment of solid tumors, autoimmune diseases, and infectious diseases. The company was founded in 2014 by Jarvis Reagan and is based in Sweden. The company is building libraries of novel T-cell immunotherapies that specifically target difficult-to-treat cancers and will be moving into clinical trials in 2024. Anocca has a fully integrated research and development infrastructure, underpinned by tailor-made advanced software solutions and in-house clinical manufacturing and process development facilities. Anocca has raised over USD 100 million in funding from leading Nordic investors and secured EUR 25 million in funding from the European Investment Bank in 2022. The company's team of over 90 employees operates from its state-of-the-art R&D and manufacturing facilities. Jarvis Reagan has been the CEO since 2014.